CD11a (LFA-1alpha) Monoclonal Antibody (R7.1), Biotin, eBioscience™, Invitrogen™

Description

• Description: This antibody specifically recognises CD11a, otherwise known as integrin alpha L chain
• Clone R7.1 recognises an epitope within the I-domain of CD11a and can be used in neutralization studies
• BMS102 is also suitable as primary antibody in staining for FACS analysis, BMS102FI can be used for direct staining of cells, BMS102BT can be used in a 2-step procedure using the biotin-(strept)avidin system
• CD11a is a 180kDa glycoprotein and member of the integrin family of cell adhesion molecules, which is expressed by all human leukocytes.CD11a combines with the CD18 beta chain (ITGB2) to form lymphocyte function-associated antigen-1 (LFA-1), and binds to its major ligands CD50 (ICAM3), CD54 (ICAM1) and CD102 (ICAM2), acting as a key mediator of cell-cell adhesion processes in normal immune and inflammatory responses
• Applications Tested: Flow Cytometry
• Purity: >95%
• CD11a (LFA-1 alpha, ITGAL) together with CD18 constitute leukocyte function-associated antigen 1 (LFA-1), the alphaLbeta2 integrin
• CD11a is implicated in activation of LFA-1 complex
• CD11a plays a central role in leukocyte intercellular adhesion through interactions with its ligands, ICAMs 1-3 (intercellular adhesion molecules 1 through 3), and also functions in lymphocyte costimulatory signaling
• CD11a is expressed on the plasma membrane of leukocytes in a low-affinity conformation
• Cell stimulation by chemokines or other signals leads to induction the high-affinity conformation, which supports tight binding of CD11a to its ligands, the intercellular adhesion molecules ICAM-1, -2, -3
• CD11a is thus involved in interaction of various immune cells and in their tissue-specific settlement, but participates also in control of cell differentiation and proliferation and of T-cell effector functions
• Blocking of CD11a function by specific antibodies or small molecules has become an important therapeutic approach in treatment of multiple inflammatory diseases
• For example, humanized anti- CD11a antibody Efalizumab (Raptiva) is being used to interfere with T cell migration to sites of inflammation, binding of cholesterol-lowering drug simvastatin to CD11a allosteric site leads to immunomodulation and increase in lymphocytic cholinergic activity
• Two transcript variants encoding different isoforms of CD11a have been found
• Diseases associated with CD11a dysfunction include benign cephalic histiocytosis and leukocyte adhesion deficiency.